Dr. Susheel Kumar Yeshala is a dedicated Medical Oncologist with over 7 years of experience in the diagnosis and treatment of solid tumors and hematological malignancies. He has expertise in systemic cancer therapies, including chemotherapy, immunotherapy, targeted therapy, and precision oncology, with a strong focus on evidence-based, personalized cancer care.
He completed his DM in Medical Oncology and holds the prestigious European Certification in Medical Oncology (ECMO). Dr. Yeshala has received advanced international exposure through clinical observerships in the United States and is actively involved in clinical research, oncology education, and multidisciplinary cancer care. He has served as faculty and speaker at several national and international oncology conferences and is a member of leading oncology societies including ASCO and ESMO.
His clinical interests include breast cancer, gastrointestinal cancers, thoracic malignancies, genitourinary cancers, CNS tumors, and molecular oncology, with a commitment to improving access to high-quality cancer care.
Qualifications:
- ECMO (European Certification in Medical Oncology) (2025)
- DM – Medical Oncology – IMS & SUM Hospital, Bhubaneswar (2022–2025)
- MD – Radiation Oncology – SGPGI, Lucknow (2016–2019)
- MBBS – SDM Medical College, Dharwad, Karnataka (2008–2014)
- AROI-ABS Brachytherapy Fellowship, USA (2020)
Areas of Expertise:
- Gastrointestinal Oncology
- Neuro-Oncology (CNS Tumours)
- Immunotherapy & Targeted Therapy
- Precision & Molecular Oncology
- Chemotherapy Administration
- Supportive & Palliative Oncology Care
Conditions Treated:
- Blood Cancers (Leukemia, Lymphoma & Myeloma)
Procedures:
- Precision Oncology-Based Treatment Planning
- Cancer Screening & Risk Assessment
- Multidisciplinary Oncology Consultation
Professional Memberships:
- Indian Society of Medical & Paediatric Oncology (ISMPO)
- European Society for Medical Oncology (ESMO)
- American Society of Clinical Oncology (ASCO)
- Association of Radiation Oncologists of India (AROI)
- Society for Immunotherapy of Cancer (SITC)
- Asian Oncology Society (AOS)
- Indian Oncology Society of India (I-OSI)
Publications:
- Real-world Data of PARP Inhibitors in First-line Maintenance for BRCA-mutated or HRD-positive Advanced Ovarian Cancer: A Multicentre Retrospective Study from India – Journal of Ovarian Research (2026)
- A Pilot Study of Perioperative Cisplatin-Capecitabine Chemotherapy with Preoperative Chemoradiation for Resectable Gastric Cancers – American Journal of Clinical Oncology (2021)
- Utility of Flow Cytometry in Diagnosis of Lymphomas from Tissue Samples – Indian Journal of Hematology and Blood Transfusion (2025)
